Paysign 2025 Q3 Earnings Record Revenue and 54.2% Net Income Growth

Paysign (PAYS) delivered a standout third-quarter 2025 performance, surpassing revenue and EPS estimates while raising full-year guidance. The company reported $21.6 million in revenue, up 41.6% year-over-year, and net income of $2.22 million, a 54.2% increase. Management attributed the results to strong demand for patient affordability programs and plasma donor solutions.

Revenue

Paysign’s revenue surged 41.6% year-over-year to $21.6 million in Q3 2025, driven by robust growth in its core segments. The plasma industry contributed $12.86 million, reflecting a 12.4% increase despite a net loss of 12 centers. Pharma patient affordability revenue jumped 142% to $7.92 million, accounting for 36.7% of total revenue, while other segments added $815,396. The company’s recent launch of 39 new pharma programs and expansion of plasma centers underscored its strategic momentum.

Earnings/Net Income

Earnings per share (EPS) rose 33.3% to $0.04 in Q3 2025, with net income reaching $2.22 million—a 54.2% year-over-year increase. This marked a record high for Q3 net income in 16 years, reflecting improved operational efficiency and strong revenue growth. The EPS outperformance and margin expansion highlight Paysign’s ability to capitalize on its expanding market share.

Post-Earnings Price Action Review

Following the earnings release, Paysign’s stock experienced mixed short-term performance. Shares rose 6.42% during the latest trading day and gained 7.05% for the week, though they declined 2.67% month-to-date. The positive reaction to the company’s record revenue and raised guidance contrasted with broader market volatility. Analysts noted the stock’s resilience, with a median 12-month price target of $9.00, implying nearly 43% upside from its November 11 closing price of $5.16.

CEO Commentary

CEO Mark Newcomer emphasized Paysign’s momentum in cross-border payment solutions and patient affordability programs, particularly in emerging markets. While macroeconomic headwinds impacted transaction volumes, the company remains focused on infrastructure investments, including enhanced fraud detection and expansion into high-growth regions. Newcomer expressed cautious optimism, citing strong customer retention and scalable platform capabilities.

Guidance

Paysign raised its full-year 2025 revenue guidance to $80.5–$81.5 million, reflecting 38.7% year-over-year growth at the midpoint. Plasma revenue is expected to account for 57% of total sales, while pharma patient affordability programs are projected to contribute 41%. The company anticipates net income of $7–$8 million ($0.12–$0.13 per share) and Adjusted EBITDA of $19–$20 million. Management emphasized disciplined cost management and technology upgrades to sustain margin stability.

Additional News

Paysign announced the opening of a new 30,000-square-foot customer service contact center, quadrupling support capacity to meet rising demand. The company also repurchased 100,000 shares of common stock during Q3, signaling confidence in its long-term value. Additionally, management highlighted the opening of 13 new patient affordability programs in October, with 20–30 more expected by year-end. These initiatives align with the CEO’s strategic focus on expanding high-value offerings and enhancing customer service infrastructure.

Analysts remain optimistic, with all five major brokerage firms rating Paysign as a “buy” or better. The company’s forward P/E ratio has dropped to 30, reflecting improved earnings expectations and investor confidence in its growth trajectory. With a robust pipeline of pharma programs and plasma centers, Paysign is positioned to maintain its upward momentum into 2026.